Brooks Laboratories Limited

Brooks Laboratories Limited

Brooks Laboratories Limited has informed the Exchange about Demerger of the Manufacturing Business into Abridge Speciality Limited, a wholly owned subsidiary, on a going concern basis. The Scheme is subject to approvals from Stock Exchanges, SEBI, NCLT, and other regulatory/statutory authorities, and the approval of shareholders and/or creditors. Upon effectiveness, the name of the Resulting Company will be changed to Brooks Laboratories Limited, and the name of the Demerged Company will be changed to Xuri Lifesciences Limited or such other name as may be approved by the Registrar of Companies.

Brooks Laboratories Limited

Brooks Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on October 14, 2026, where the Board approved the Scheme of Arrangement between the Company, Abridge Speciality Limited, and their respective shareholders, under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, for the demerger of the Manufacturing Business of the Demerged Company into the Resulting Company.

Brooks Laboratories Limited

Brooks Laboratories Limited has responded to a query from the National Stock Exchange regarding a significant movement in its share price, stating that it has disclosed all material information and is not aware of the reason for the price change.

Brooks Laboratories Limited

Brooks Laboratories Limited has observed significant price movement, prompting the NSE to write to the company for a response.

Brooks Laboratories Limited

Brooks Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30th September 2026.

Brooks Laboratories Limited

Brooks Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window will be closed for the Designated Persons and their immediate relatives effective from Thursday, 1st October, 2026, until 48 hours after the declaration of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026.

Brooks Laboratories Limited

Brooks Laboratories Limited has informed the Exchange regarding the resignation of Ms. Krutika Rane as Company Secretary and Compliance Officer of the Company, effective October 9, 2026, to pursue an alternate career opportunity.

Brooks Laboratories Limited

Brooks Laboratories Limited has informed the Exchange about the resignation of a Director/KMP/SMP.

Brooks Laboratories Limited

Brooks Laboratories Limited has published a newspaper advertisement regarding a special window for re-lodgment of transfer requests of physical shares, as per SEBI Circular No. HO/38/13/11(2)/2026-MIRSD-POD/I/3750/2026.

Brooks Laboratories Limited

Brooks Laboratories Limited has submitted the Exchange a copy Scrutinizers report of Annual General Meeting held on September 03, 2026, and informed the Exchange regarding voting results.

Brooks Laboratories Limited

Brooks Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 03, 2026. The 24th Annual General Meeting of shareholders of the Company was held through Video Conferencing and Other Audio-Visual Means. The meeting was attended by 319 Members, and the requisite quorum was present. The meeting was chaired by Dr. Usha Singh, Non-Executive - Independent Director. Various resolutions were passed, including the adoption of Annual Audited Standalone and Consolidated Ordinary Resolutions, appointment of Director, ratification of Remuneration of Cost Auditors, and approval of Related Party Transactions.

Brooks Laboratories Limited

Brooks Laboratories Limited has published an addendum to the notice of its 24th Annual General Meeting, which will be held on September 3rd. The addendum was published in two newspapers, Financial Express and Jansatta, on August 22nd.

Brooks Laboratories Limited

Brooks Laboratories Limited has issued an addendum to the notice of its 24th Annual General Meeting, scheduled to be held on September 3, 2026, to inform shareholders of changes in Resolution No. 4 and its explanatory statement regarding a corporate guarantee arrangement.

Brooks Laboratories Limited

Brooks Laboratories Limited has informed the Exchange regarding 'Intimation Of Record Date, E-Voting Dates And Book Closure Date'. The company has announced the record date, e-voting dates, and book closure date for its 24th Annual General Meeting. The book closure period will be from August 27, 2026, to September 3, 2026, and the e-voting period will be from August 31, 2026, to September 2, 2026.

Brooks Laboratories Limited

Brooks Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

Brooks Laboratories Limited

Brooks Laboratories Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with a net profit of Rs. 141.86 lakhs and a loss of Rs. 178.69 lakhs for the standalone and consolidated entities respectively.

Brooks Laboratories Limited

Brooks Laboratories Limited has announced the 24th Annual General Meeting (AGM) to be held on September 3, 2026, through Video Conference/Other Audio-Visual Means.

Brooks Laboratories Limited

Brooks Laboratories Limited has announced the 24th Annual General Meeting (AGM) and Annual Report for the FY 2025-26. The AGM will be held on September 3, 2026, through video conferencing. The company has also sent a letter to shareholders who have not registered their email addresses, providing a web-link to access the Annual Report.

Brooks Laboratories Limited

Brooks Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 03, 2026.

Brooks Laboratories Limited

Brooks Laboratories Limited has intimated the 24th Annual General Meeting through a newspaper publication, to be held on 3rd September 2026 through Video Conference (VC)/Other Audio-Visual Means (OAVM).